😌I remember WAY back in 2012 when I started this lung cancer advocacy journey with Dr. David Tom Cooke H. Jack West, MD Janet Freeman-Daily and Faces of Lung Cancer, these biomarkers weren’t being discussed on this level. I am in awe of the advancements made! 💕🥲 cc: Matthew Katz, MD 🟦 #lcsm #ASCO24

#ASCO24 is tomorrow!

Lung Cancer Abstracts not to missed👇

My Top 5 Targeted Therapy abstracts, with key data where available

Get your thinking caps on for tomorrow
ASCO ESMO - Eur. Oncology IASLC #ASCOLDP22
#ESMOCorrespondents Annals of Oncology #IrishLungCancerCommunity EGFR Resisters KRASKickers

Mike Thompson, MD, PhD, FASCO Matthew Katz, MD 🟦 PF Anderson @[email protected] Liz Salmi Janet Freeman-Daily Audun Utengen Don S. Dizon MD (he/him) 🇬🇺 Charlie Blotner Dr. David Tom Cooke Dee Sparacio Alicia C. Staley Michael Fisch MD MPH Colleen Young David Rattai JCO Clinical Cancer Informatics #ASCO24 Don’t forget to tag the biomarker-driven patient advocacy groups to continue to engage patients.

We have a growing list of #lcsm 🫁 groups:
ALK Positive EGFR Resisters Exon 20 Group, a multi-stakeholder organization RETpositive BrafBombers METCrusaders KRASKickers NTRKers The ROS1ders, Inc.

We are less than 2 weeks away from our 4th Annual Living with EGFR-Mutant Lung Cancer Forum. Take a look at our speakers!

Pts' Preferences for Adj Osi in NSCLC After Complete Surgical Resection: What makes it worth it to Pts?

“This study explores pts preferences without complete OS data. Factors include employment, education & willingness to pay.”

clinical-lung-cancer.com/article/S1525-…

#ASCO24 is like the Cannes Film Festival. Exciting, energetic, w/ a flurry of #lungcancer updates! Like any film festival, there are the blockbusters (LAURA, ADRIATIC, PALOMA-3). However, I want to highlight 10 great abstracts (“indie” darlings) that may be missed! [THREAD]

Very important research by Dr. Nishwant Swami, MD, MPH as we try to understand risk factors for lung cancer in people with no previous tobacco use.

Please stop by our poster at #88 Monday!

#ASCO24

#FlorezLab OncoAlert Oncogene Cancer Research Young Lung Cancer Initiative EGFR Resisters R. Taylor Ripley, M.D. Thoracic Surgeon

Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms

onlinelibrary.wiley.com/doi/10.1111/ca…

2 years after receiving the Conquer Cancer, the ASCO Foundation WWCC Latina YIA, I’m ecstatic to put my proud mentor hat during this #ASCO24 CCF Award Ceremony and celebrate:
🌟superstar Maria Antonia Vélez YIA (🔜 UCLA ThoracicOnc Faculty)
🌟Kevin Reyes (@UCSFMedicine MS4) MSR & AMRA Awards
🌟8️⃣

Very exciting to see a drug targeting TP53. Hope this succeeds and is the first of many agents.

Top US Physician Social Influencers in Lung Cancer: What do they do that makes them great?
👉blog.uptempogroup.com/uptempo-blog/t…

Helpful KOLs to follow for #ASCO24 #LCSM insights:
Stephen V Liu, MD Nathan A. Pennell MD, PhD, FASCO H. Jack West, MD Balazs Halmos Patrick Forde Charu Aggarwal, MD, MPH, FASCO Brendon Stiles

For those who followed Elizabeth’s cancer journey, you will recall that she always wore superhero shirts to her various appointments.

I took several of my favorites and turned them into a quilt. “Forever My Superhero”
#LCSM

Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC

sciencedirect.com/science/articl…

Amazing curated list of abstracts for #ASCO24 in lung cancer

Promises to be great session @asco please considering joining us as we discuss advances in AI in clinical oncology!

ADC shows promising results in phase 1 study

🎯YL202/BNT326 targets HER3
🎯Pts w/ EGFR NSCLC & HR +/HER2- breast cancer
🎯Out of the 46 pts, 1 CR, 16 PR & 26 pts w/ stable disease
🎯 Demonstrated an acceptable safety and tolerability profile

ctol.digital/news/medilink-…

Leptomeningeal disease- is one of the biggest areas of need and data in the mgmt of patients with EGFR+ lung cancer. Pts excluded from most clinical trials which does not help us find solutions 👇🏽EGFR Resisters #lcsm

Different genetic profiles contribute to worse overall survival in patients with leptomeningeal metastases of non-small-cell lung cancer

“Patients with LM & TP53mutations presented with worse OS. LM patients with EGFR_amp had a shorter OS.”

link.springer.com/article/10.100…

Let's do better & reduce the time to diagnosis for young lung cancer patients

Medical Professionals: Please consider lung cancer in your differential diagnoses. Quicker diagnoses may mean better outcomes. Lung cancer DOES happen to young people with no traditional risk factors

🏮Beamion LUNG-1: Zongertinib in pts w/ HER2 aberration + (ph 1a) & HER2 mutation + mNSCLC (ph 1b)

Ph 1a
▫️36 pts w/ NSCLC
▫️ORR 58%; DCR 97%
Ph 1b
▫️ 23 pts
▫️ORR 74%; DCR 91%
▫️AEs: diarrhea, rash

Emerging TKIs in the #HER2 space. ASCO OncoAlert #ASCO24 #lcsm